Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGHT Trial: Sex Hormones to Reverse Inguinal Hernias in Males
NCT07604272Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in inguinal hernia comparing Fulvestrant 250 mg with Anastrozole 1 mg (2 arms). Primary endpoint: Composite Safety Event Rate at 6 months. Started Oct 2026; status: recruiting.
02
Drugs
fulvestrantanastrozole
03
Conditions
inguinal hernia
Beyond the preview
Go deeper on NCT07604272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604272.